Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Attard

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|December 5, 2013
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'A Omlin, C J Pezaro, S Zaidi, et al.
Proceedings. Biological Sciences|December 1, 2021
New Zealand's extinct giant raptor (<i>Hieraaetus moorei</i>) killed like an eagle, ate like a condorA H van Heteren, S Wroe, L R Tsang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer|August 27, 2009
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementC S Foster, A R Dodson, L Ambroisine, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 14, 2024
Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP TrialP H Patel, S Dreibe, A Reid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)L R Molife, G Attard, P C Fong, et al.
Oncogene|October 9, 2007
Complex patterns of ETS gene alteration arise during cancer development in the human prostateJ Clark, G Attard, S Jhavar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
Oncogene|July 20, 2007
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerG Attard, J Clark, L Ambroisine, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|December 5, 2013
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'A Omlin, C J Pezaro, S Zaidi, et al.
Proceedings. Biological Sciences|December 1, 2021
New Zealand's extinct giant raptor (<i>Hieraaetus moorei</i>) killed like an eagle, ate like a condorA H van Heteren, S Wroe, L R Tsang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
British Journal of Cancer|August 27, 2009
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementC S Foster, A R Dodson, L Ambroisine, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 14, 2024
Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP TrialP H Patel, S Dreibe, A Reid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)L R Molife, G Attard, P C Fong, et al.
Oncogene|October 9, 2007
Complex patterns of ETS gene alteration arise during cancer development in the human prostateJ Clark, G Attard, S Jhavar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
Oncogene|July 20, 2007
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerG Attard, J Clark, L Ambroisine, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Pageof 8